Data obtained from the prostate cancer prevention trial (PCPT) indicates that up to 15% of males with a normal screening test (PSA level <4 ng/ml and negative digital rectal examination) have biopsy-detectable prostate cancer (10). This evidence concerns the gene KLK3 and prostate carcinoma.